Streetbeat News

Regulatory

SLNH

Soluna Holdings (NASDAQ: SLNH), the parent company of Soluna Computing, has been granted a 180-day extension by Nasdaq to regain compliance with the minimum per share bid price requirement. The company now has until December 18, 2023, to meet the $1 minimum per share bid requirement.

Portfolio Pulse from Happy Mohamed

June 26, 2023 | 12:07 pm

OCEA

Ocean Biomedical has been granted a US patent for its bispecific cancer immunotherapy treatment, which has demonstrated the ability to kill tumor cells in lung cancer, brain cancer (glioblastoma), and metastatic melanoma.

Portfolio Pulse from Bill Haddad

June 26, 2023 | 12:06 pm

NSPR

InspireMD has completed enrollment for its C-Guardians U.S. Investigational Device Exemption clinical trial, aimed at supporting potential U.S. marketing approval of the CGuard Prime EPS stent system. The company expects study results and Premarket Approval submission in H2 2024, with potential U.S. approval in H1 2025.

Portfolio Pulse from Happy Mohamed

June 26, 2023 | 12:04 pm

PRTG

Portage Biotech (NASDAQ:PRTG) has dosed the first patient in its Phase 1a trial, ADPORT-601, evaluating the adenosine 2A receptor (A2AR) antagonist candidate, PORT-6, in patients with solid tumors including prostate cancer, renal, and non-small cell lung cancer. The trial aims to evaluate the safety and efficacy of PORT-6 and plans to integrate proprietary biomarkers for patient selection.

Portfolio Pulse from Benzinga Newsdesk

June 26, 2023 | 12:03 pm

BNTC

Benitec Biopharma has received FDA clearance for the Investigational New Drug (IND) application for BB-301, a treatment for oculopharyngeal muscular dystrophy (OPMD).

Portfolio Pulse from Benzinga Newsdesk

June 26, 2023 | 12:02 pm

FEMY

Femasys has announced FDA approval of its Investigational Device Exemption (IDE) for a pivotal clinical trial of FemBloc, a non-surgical permanent birth control alternative for women.

Portfolio Pulse from Bill Haddad

June 26, 2023 | 12:01 pm

LIAN

LianBio has received marketing approval for its drug CAMZYOS in Singapore.

Portfolio Pulse from Bill Haddad

June 26, 2023 | 12:00 pm

LLY

Eli Lilly announced that its SURMOUNT-2 study results published in The Lancet show tirzepatide achieved a mean weight reduction of 15.7% at the highest dose (15 mg) in adults with obesity or overweight and type 2 diabetes.

Portfolio Pulse from Charles Gross

June 26, 2023 | 11:49 am

AVTX

Avalo announced positive topline data from its Phase 2 PEAK trial for AVTX-002 in patients with non-eosinophilic asthma, indicating potential for the drug's future development.

Portfolio Pulse from Benzinga Newsdesk

June 26, 2023 | 11:38 am

ADMP

Adamis Pharmaceuticals has received an undisclosed amount of grant funding from the National Institutes of Health (NIH) for the development of a treatment for alcohol use disorder.

Portfolio Pulse from Bill Haddad

June 26, 2023 | 11:37 am